The DOI matches its Crossref record; 102 of the 102 references it cites were found in a registry or an index; 57 of the 96 sources its claims cite were checked for support.
Cholinesterase Inhibitors from Plants and Their Potential in Alzheimer’s Treatment: Systematic Review
Open accessAbstract
INTRODUCTION: Alzheimer's disease (AD) is a neurodegenerative disorder characterized by memory loss and cognitive decline, primarily due to dysfunction of acetylcholine caused by acetylcholinesterase and butyrylcholinesterase. While synthetic cholinesterase inhibitors like donepezil, rivastigmine, and galantamine are commonly used, they have notable side effects, prompting interest in natural alternatives. Medicinal plants, rich in bioactive compounds like flavonoids and alkaloids, have shown potential as cholinesterase inhibitors with additional antioxidants and anti-inflammatory benefits. This study aimed to evaluate the cholinesterase-inhibiting effects of various plant species and their compounds to identify new therapeutic candidates and reduce side effects. METHOD: A PRISMA-compliant review was conducted, screening studies from multiple databases, with a final inclusion of 64 in vivo studies. RESULTS: , which improved memory, reduced oxidative stress, and provided neuroprotection. Some extracts also reduced amyloid plaques, enhanced neuronal integrity, and restored cholinesterase activity, indicating their potential as therapeutic agents for AD and other neurodegenerative diseases. CONCLUSIONS: The findings underscore the promise of plant-based compounds in treating cognitive decline and cholinergic dysfunction in AD, advocating for further research into their therapeutic potential.
Overview
CoChat Summary
TL;DR
This PRISMA-guided systematic review assessed whether plant species and their components inhibit cholinesterase activity in Alzheimer’s-related neuron and animal models. It included 64 in vivo studies and concluded that many plant extracts and compounds reduced AChE and/or BChE activity while also improving memory, oxidative stress, and other neuroprotective outcomes.
Key findings
- The search yielded 1,571 records; after screening and eligibility assessment, 64 articles met inclusion criteria.
- Included studies were all in vivo animal models of Alzheimer’s disease or Alzheimer’s-like impairment, with scopolamine the most common inducer (n = 39), followed by AlCl3 (n = 9), Aβ (n = 6), STZ (n = 4), TMT (n = 2), transgenic dementia models (n = 2), H2O2 (n = 1), and 3-NPA (n = 1).
- Across the included studies, plant extracts and compounds frequently reduced AChE and/or BChE activity and improved cognition, including examples such as Ferula ammoniacum and Elaeagnus umbellata in scopolamine models, Canna indica and Centella asiatica in AlCl3 models, and Evolvulus alsinoides and Clitoria ternatea in STZ models.
- The review states that many extracts also showed antioxidant, anti-inflammatory, reduced amyloid plaque, and enhanced neuronal integrity effects, suggesting multitarget potential beyond cholinesterase inhibition.
Methods
- PRISMA-compliant systematic review with protocol registered in PROSPERO (CRD42025585536).
- Searched Medline (OvidSP), Embase (OvidSP), Web of Science Core Collection, PubMed, and Scopus from 29 August to 1 September 2024.
- Included original in vivo animal studies of Alzheimer’s disease or Alzheimer’s-like models assessing plant extracts or isolated compounds for direct effects on AChE and/or BChE; data were extracted by three independent reviewers and qualitatively synthesized.
Limitations
- The paper states that only in vivo animal studies were included; it excludes humans, in silico studies, molecular docking, isolated-enzyme studies, and studies without control groups, which limits direct clinical inference.
- The text makes evident that the evidence base is heterogeneous in models, species, plant materials, doses, and routes of administration, which likely limits comparability across studies (not stated explicitly as a limitation).
- The paper does not report a formal risk-of-bias or meta-analysis in the provided text, so the synthesis appears qualitative only (not stated in the paper).
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
33 Valid · 2 Not valid · 20 Not checked · 9 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“AChE, responsible for the breakdown of ACh, is typically elevated in AD patients, especially in the cortex and hippocampus, contributing to cognitive impairment.”
§ Cholinesterase Inhibitors from Plants and Their Potential in Alzheimer’s Treatment: Systematic Review > 1. Introduction
What the sources say
- Disputedcites [6] Mushtaq, 2014, Status of acetylcholinesterase and butyrylcholinesterase in Alzheimer’s disease and type 2 diabetes mellitus, CNS Neurol. Disord. Drug Targets sourceExperimental — accuracy not yet measured
The Introduction says AChE levels fall by as much as 85% in certain brain areas in AD, while BuChE levels rise; it also reports a changed BuChE-to-AChE ratio in cortical areas. The section on targeting these enzymes likewise says AChE activity declines as AD progresses, contrary to the claim that AChE is typically elevated. (LLM, conf=0.91)
Checked by a reasoning model — may be wrong.
- Disputedcites [7] Nordberg, 2013, A review of butyrylcholinesterase as a therapeutic target in the treatment of Alzheimer’s disease, Prim. Care Companion CNS Disord. sourceExperimental — accuracy not yet measured
The Results section on cholinesterase activity says AChE activity is decreased, not typically elevated, in certain AD brain regions. The section on expression also reports decreases in synaptic AChE and in a major AChE form in the hippocampus and cortex. Page numbers were not supplied. (LLM, conf=0.93)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“The diverse mechanisms through which these plant extracts exert their effects—ranging from ChE inhibition to antioxidant activity—suggested that they may serve as valuable adjuncts or alternatives to conventional pharmacological treatments for AD [103,104].”
§ Cholinesterase Inhibitors from Plants and Their Potential in Alzheimer’s Treatment: Systematic Review > 4. Discussion
What the sources say
- Not checked — no full text of the sourcecites [103] Jabir, 2018, Cholinesterase targeting by polyphenols: A therapeutic approach for the treatment of Alzheimer’s disease, CNS Neurosci. Ther. source
- Supportedcites [104] Andrade, S., Ramalho, M.J., Loureiro, J.A., and Pereira, M.d.C. (2019). Natural Compounds for Alzheimer’s Disease Therapy: A Systematic Review of Preclinical and Clinical Studies. Int. J. Mol. Sci., 20. source
The Discussion describes plant-derived extracts as potential ways to treat AD through different therapeutic mechanisms. The clinical-trials section calls natural compounds an emerging approach to AD therapy and reports cognitive improvements with several plant extracts. This supports the hedged suggestion that such extracts may be therapeutic options, though it does not establish their effectiveness as adjuncts to conventional drugs. (LLM, conf=0.85)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on 2 assumptions not shown here.
Every source the paper cites for this claim was checked and supports it.
In the paper
“essential oils from Pistacia khinjuk leaves (PKEO) and Allium sativum cloves (ASEO) showed strong AChE and BChE inhibitory effects in rats, suggesting their potential as treatments for Alzheimer’s [82].”
§ Cholinesterase Inhibitors from Plants and Their Potential in Alzheimer’s Treatment: Systematic Review > 3. Results > 3.4. Neuroprotective Effects of Plant Extracts and Essential Oils in Amyloid Beta (Aβ)-Induced Alzheimer’s Disease Models Various plant extracts and essential oils have demonstrated neuroprotective effects against Alzheimer’s-like symptoms by modulating AChE activity and enhancing cognitive function. Chamaecyparis obtusa essential oil (1 mL/cage via inhalation) in rats exhibited cognitive improvement, decreased AChE activity, and prevented neuronal apoptosis after Aβ-induced damage [77]. Bacopa monnieri extract (40–80 mg/kg) reduced Alzheimer’s-like symptoms in Aβ42-injected rats by improving cognitive function, preserving hippocampal neurons, modulating the GSK-3β/Wnt/β-catenin pathway, and significantly decreasing AChE activity at 80 mg/kg [78]. Pinus densiflora extract (15–30 mg/kg) improved cognitive function and reduced AChE activity, while increasing antioxidant levels, reducing neuroinflammation, and enhancing mitochondrial activity in Aβ-treated ICR mice [79]. Cistanche tubulosa aqueous extract (100–200 mg/kg) improved cognitive function, reduced amyloid deposition, and reversed cholinergic and dopaminergic dysfunction, with the 200 mg/kg dose significantly decreasing cortical AChE activity in Aβ-infused rats [80]. Blueberry leaf extract (ethyl acetate fraction, 5–20 mg/kg) alleviated Aβ-induced memory impairment by inhibiting AChE activity and oxidative stress in Aβ-treated mice [81]. Additionally, essential oils from Pistacia khinjuk leaves (PKEO) and Allium sativum cloves (ASEO) showed strong AChE and BChE inhibitory effects in rats, suggesting their potential as treatments for Alzheimer’s [82].
What the sources say
- Supportedcites [82] Ghajarbeygi, 2019, An in vitro and in vivo cholinesterase inhibitory activity of Pistacia khinjuk and Allium sativum essential oils, J. Pharmacopunct. source
The Abstract Conclusion describes PKEO and ASEO as potent AChE and BChE inhibitors in rats and says they hold promise for Alzheimer’s disease treatment. The Results also report that both oils reduced enzyme activity in rats, while the Conclusion identifies the oils as derived from P. khinjuk leaves and A. sativum cloves. (LLM, conf=0.93)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Phytochemicals like alkaloids, flavonoids, and terpenoids have demonstrated potential in addressing neurodegenerative diseases (NNDs), including AD, by combating oxidative stress, minimizing inflammation, and protecting neurons [13,14].”
§ Cholinesterase Inhibitors from Plants and Their Potential in Alzheimer’s Treatment: Systematic Review > 1. Introduction
What the sources say
- Supportedcites [13] Riaz, 2023, Phytobioactive compounds as therapeutic agents for human diseases: A review, Food Sci. Nutr. source
The Alkaloids section describes berberine’s antineurodegenerative potential, attenuation of neuroinflammation, and protection of neurons. The Polyphenols section links the flavonoid quercetin to potential treatment of Alzheimer’s disease, while the Terpenes section describes neuroprotective, anti-inflammatory, and oxidative-stress-inhibiting effects. Page numbers are not provided in our copy. (LLM, conf=0.88)
- Partly supportedcites [14] Sun, W., and Shahrajabian, M.H. (2023). Therapeutic Potential of Phenolic Compounds in Medicinal Plants-Natural Health Products for Human Health. Molecules, 28. sourceExperimental — accuracy not yet measured
The Resveratrol section (no page supplied) reports neuroprotective effects through antioxidant and anti-inflammatory pathways and potential application to Alzheimer’s disease; the Conclusions also identify neuroprotective potential among the benefits of phenolic compounds. But the paper does not extend that neurodegenerative-disease claim to all three named groups: its Introduction mentions alkaloids and terpenoids in connection with diabetes, not neuronal protection. (LLM, conf=0.88)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Additionally, increased BChE activity, especially in the hippocampus and temporal cortex, may exacerbate this cognitive decline by promoting amyloid-beta aggregation and plaque formation, which are key features of AD [94,95].”
§ Cholinesterase Inhibitors from Plants and Their Potential in Alzheimer’s Treatment: Systematic Review > 4. Discussion
What the sources say
- Partly supportedcites [94] Asik, 2017, Antioxidant and Cholinesterase Inhibitory Activities of Ethyl Acetate Extract of Terminalia chebula: Cell-Free in Vitro and in Silico Studies, Pharmacogn. Mag. sourceExperimental — accuracy not yet measured
The Results and Discussion section says BuChE levels rise as Alzheimer’s disease progresses and links BuChE to plaque changes and neuronal degeneration. It does not locate increased BuChE activity in the hippocampus or temporal cortex; its hippocampus passage concerns AChE instead. The source therefore supports the general BuChE–plaque link, but not the claim’s anatomical specificity. (LLM, conf=0.88)
- Partly supportedcites [95] Sikora, 2017, Metformin and Its Sulfenamide Prodrugs Inhibit Human Cholinesterase Activity, Oxid. Med. Cell. Longev. sourceExperimental — accuracy not yet measured
The Discussion (page not provided) says BuChE activity increases as Alzheimer’s disease progresses and reports that BuChE inhibition in aged rats improved cognitive function and decreased amyloid deposits. It does not identify the hippocampus or temporal cortex as sites of increased BuChE activity, or say that BuChE promotes amyloid-beta aggregation and plaque formation. (LLM, conf=0.85)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
14 more claims · 1 with their cited sources checked
Create a free account to see all 64 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 40
- The quote only partly states this claim. 1
- Probably not a substantial claim. 8
Citations
Cites
The PRISMA 2020 statement: An updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · BMJ · doi:10.1136/bmj.n71 · Cited by 108,283
Page, M. J., Moher, D., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · BMJ · doi:10.1136/bmj.n160 · Cited by 13,262 · cited 1×
“This study was performed according to the standards of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) (Table S1) [23,24].”
Alzheimer Disease: An Update on Pathobiology and Treatment Strategies
Long, J. M., & Holtzman, D. M. (2019) · Cell · doi:10.1016/j.cell.2019.09.001 · Cited by 3,204
Comprehensive Review on Alzheimer’s Disease: Causes and Treatment
Breijyeh, Z., & Karaman, R. (2020) · Molecules · doi:10.3390/molecules25245789 · Cited by 2,789 · cited 1×
“AD is characterized by neurodegeneration due to neuronal cell death, starting in the entorhinal cortex of the hippocampus, primarily affecting individuals aged 65 and older [1].”
Plant-Derived Natural Products: A Source for Drug Discovery and Development
Chaachouay, N., & Zidane, L. (2024) · Drugs and Drug Candidates · doi:10.3390/ddc3010011 · Cited by 1,081 · cited 1×
“These plants are a source of bioactive compounds with potential pharmacological benefits, including antibacterial, anti-inflammatory, and neuroprotective effects [11,12].”
Sun, W., & Shahrajabian, M. H. (2023) · Molecules · doi:10.3390/molecules28041845 · Cited by 806 · cited 1×
“Phytochemicals like alkaloids, flavonoids, and terpenoids have demonstrated potential in addressing neurodegenerative diseases (NNDs), including AD, by combating oxidative stress, minimizing inflammation, and protecting neurons [13,14].”
Alzheimer’s disease hypothesis and related therapies
Du, X., Wang, X., & Geng, M. (2018) · Translational Neurodegeneration · doi:10.1186/s40035-018-0107-y · Cited by 607 · cited 2×
“The main pathological features include amyloid beta (A β ) accumulation, tau pathology, and cholinergic dysfunction [4,5].”
Drug treatments in Alzheimer’s disease
Briggs, R., Kennelly, S. P., & O’Neill, D. (2016) · Clinical Medicine · doi:10.7861/clinmedicine.16-3-247 · Cited by 571 · cited 2×
“It is used for moderate-to-severe AD and can be combined with ChEIs to improve cognitive function [8–10].”
Kwon, S.-H., Lee, H.-K., Kim, J.-A., Hong, S.-I., Kim, H.-C., Jo, T.-H., Park, Y.-I., Lee, C.-K., Kim, Y.-B., Lee, S.-Y., et al. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.09.001 · Cited by 437 · cited 1×
“Moreover, chlorogenic acid extract demonstrated neuroprotective effects by reducing AChE activity, oxidative stress, and memory impairment, while wild ginseng also improved learning and reduced cholinergic loss and AChE activity in the hippocampus [57,58].”
Santos, T. C. D., Gomes, T. M., Pinto, B. A. S., Camara, A. L., & Paes, A. M. D. A. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01192 · Cited by 389
Research works printed but not linked: 1
- Ibrahim, 2016, Anti-acetylcholinesterase, anti-inflammatory and anti-oxidant activities of Mentha longifolia for treating alzheimer disease, Der Pharm. Lett., 8, 34
Cited by
Karakuş, Z. (2026) · International Journal of Secondary Metabolite · doi:10.21448/ijsm.1721228 · Cited by 14
El-Sheekh, M. M., Bases, E., Shafay, S. M. E., El‐Shenody, R. A., Elshobary, M. E., Wahab, A. H. A. A., Yousuf, W. E., Essa, D. I., & Alkafaas, S. S. (2025) · Pharmaceuticals · doi:10.3390/ph18111720 · Cited by 6
Çömlekçioğlu, N., Sevindik, М., Gürgen, A., Sevindik, E., Uysal, İ., & Koçer, O. (2025) · Scientific Reports · doi:10.1038/s41598-025-31940-z · Cited by 4
“To ensure experimental reproducibility and minimize genetic drift, all antiproliferative assays were conducted using cells between passages 5 and 15.”
Shah, L., Iqbal, A., Imran, M., Jan, M. S., Elsharkawy, E. R., & Shah, Z. (2025) · Chemistry & Biodiversity · doi:10.1002/cbdv.202500947 · Cited by 1
Nădășan, I., Babotă, M., Rusu, A., & Tanase, C. (2025) · Plants · doi:10.3390/plants14192966 · Cited by 2
“The inhibition of both enzymes has been linked to a neuroprotective effect and therefore, to the prevention of neurodegenerative diseases, although in vivo tests should also be employed to assess the actual applicability of these results [118–120].”
Metadata
- Authors
- ALNasser, M. N., Alboraiy, G. M., Alsowig, E. M., & Alqattan, F. M.
- Affiliations
- King Faisal University (SA)
- Corresponding author
- ALNasser, Maryam N.
- ORCID
- ALNasser, Maryam N.
- Venue
- Brain Sciences
- Publisher
- MDPI AG
- Published
- 2025-02-19
- Volume
- 15
- Issue
- 2
- Pages
- 215
- ISSN
- 2076-3425 (ISSN-L)
- PMC
- PMC11852592
- OpenAlex
- W4407740417
- Semantic Scholar
- 92c3bb9081db1f0f18880fdb42ca9a4482830741
- Cited by
- 35
- References
- 14
- Citations by year
- 2026: 25 · 2025: 10
- FWCI
- 4.70
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Brain Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Deanship of Scientific Research, Vice Presidency for Graduate Studies and Scientific Research, King Faisal University, Saudi Arabia (KFU250395)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Health Sciences › Medicine › Complementary and alternative medicine › Medicinal Plants and Neuroprotection
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- cholinesterase inhibitors, Alzheimer's disease, medicinal plants, acetylcholinesterase, butyrylcholinesterase, flavonoids, alkaloids, neuroprotection, oxidative stress, amyloid plaques, cognitive decline, cholinergic dysfunction, plant extracts
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cholinesterase Inhibitors from Plants and Their Potential in Alzheimer’s Treatment: Systematic Review. https://app.cochat.ai/papers/10.3390/brainsci15020215
- The paper
- ALNasser, M. N., Alboraiy, G. M., Alsowig, E. M., & Alqattan, F. M. (2025). Cholinesterase Inhibitors from Plants and Their Potential in Alzheimer’s Treatment: Systematic Review. Brain Sciences. https://doi.org/10.3390/brainsci15020215
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.